6 Department of Pathology, University of California at San Francisco Medical Center, San
|
|
- Augustus Whitehead
- 5 years ago
- Views:
Transcription
1 The Impact of Stage, Grade, and Mucinous Histology on the Efficacy of Systemic Chemotherapy in Adenocarcinomas of the Appendix: Analysis of the National Cancer Data Base Elliot A. Asare, MD 1,2 ; Carolyn C. Compton, MD, PhD 3 ; Nader N. Hanna, MD 4 ; Lauren A. Kosinski, MD 2 ; Mary Kay Washington, MD, PhD 5 ; Sanjay Kakar, MD 6 ; Martin R. Weiser, MD 7 ; and Michael J. Overman, MD 8 BACKGROUND: Adenocarcinomas of the appendix represent a heterogeneous disease depending on the presence of mucinous histology, histologic grade, and stage. In the current study, the authors sought to explore the interplay of these factors with systemic chemotherapy in a large population data set. METHODS: Patients in the National Cancer Data Base (NCDB) who were diagnosed with mucinous, nonmucinous, and signet ring cell-type appendiceal neoplasms from 1985 through 2006 were selected. Multivariable Cox proportional hazards regression models were developed. RESULTS: A total of 11,871 patients met the inclusion criteria for the current study: 50.3% had mucinous neoplasms, 40.5% had nonmucinous neoplasms, and 9.2% had signet ring cell-type neoplasms. The 5-year overall survival (OS) stratified by grade was similar among patients with American Joint Committee on Cancer stage I to stage III disease but not for those with stage IV disease. The median OS for patients with stage IV mucinous and nonmucinous tumors was 6.4 years and 2.3 years, respectively, for those with well differentiated histology (P<.0001) and was 1.5 years and 0.8 years, respectively, for those with poorly differentiated histology (P<.0001). In multivariable modeling for stage I to III disease, adjuvant chemotherapy improved OS for both mucinous and nonmucinous histologies, with hazard ratios (HRs) of 0.78 (95% confidence interval [95% CI], [P ]) and 0.83 (95% CI, [P 5.002]), respectively. For patients with stage IV disease, systemic chemotherapy significantly improved OS for those with nonmucinous (HR, 0.72; 95% CI, [P<.0001]) but not mucinous (HR, 0.95; 95% CI, [P 5.2) histologies, although this was grade-dependent. The median OS for chemotherapy versus no chemotherapy was 6.4 years versus 6.5 years (P value not significant) for patients with mucinous, well-differentiated tumors and 1.6 years versus 1.0 years (P ) for patients with mucinous, poorly differentiated tumors. CONCLUSIONS: Adjuvant chemotherapy demonstrated a significant OS benefit regardless of histology. However, for patients with stage IV disease, the benefit of systemic chemotherapy varied by tumor histology and grade, with patients with well-differentiated, mucinous, appendiceal adenocarcinomas deriving no survival benefit from systemic chemotherapy. Cancer 2016;122: VC 2015 American Cancer Society. KEYWORDS: appendix, chemotherapy, mucinous, nonmucinous, survival. INTRODUCTION Adenocarcinomas of the appendix are histologically sorted into mucinous, nonmucinous, and signet ring cell types. 1,2 The seventh edition of the American Joint Committee on Cancer (AJCC) staging system separated appendiceal adenocarcinomas from colorectal adenocarcinomas and incorporated grade into the staging of stage IV disease. 3 The current AJCC staging system for appendiceal adenocarcinomas classifies mucinous tumors into low-grade (well-differentiated) and high-grade (moderately and poorly differentiated) adenocarcinomas. 3 This distinction is required for the classification of stage IV appendiceal adenocarcinomas as low-grade mucinous adenocarcinoma with peritoneal-only involvement are classified as stage IVA. Given the rarity of appendiceal neoplasms, the majority of the existing reports in the literature are classified as singleinstitution retrospective studies and hence have been limited by small sample size and selection bias. 4-7 Prior reports have demonstrated the prognostic impact of histological grade for appendiceal adenocarcinomas with mucinous histology. 8,9 Corresponding author: Michael J. Overman, MD, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030; Fax: (713) ; moverman@mdanderson.org 1 Cancer Programs, American College of Surgeons, Chicago, Illinois; 2 Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin; 3 Department of Pathology, Arizona State University, Phoenix, Arizona; 4 Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland; 5 Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee; 6 Department of Pathology, University of California at San Francisco Medical Center, San Francisco, California; 7 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; 8 Department of Hematology and Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Previously presented as an abstract at: 12th Annual Gastrointestinal Cancer Symposium; January 15-17, 2015; San Francisco, CA. Published in J Clin Oncol. 2015;33(suppl 3):Pages. Abstract 668. Additional supporting information may be found in the online version of this article. DOI: /cncr.29744, Received: April 29, 2015; Revised: August 22, 2015; Accepted: September 2, 2015, Published online October 27, 2015 in Wiley Online Library (wileyonlinelibrary.com) Cancer January 15,
2 In a recent analysis of Surveillance, Epidemiology, and End Results (SEER) data, 2469 appendiceal adenocarcinomas were analyzed and the prognostic impact of histologic grade for mucinous tumors was found to be limited to stage IV disease. 8 In addition, a significant difference in cancer-specific survival (CSS) between patients with moderately differentiated and poorly differentiated mucinous appendiceal adenocarcinomas was noted. 8 However, this analysis was limited by sample size and the lack of any treatment-related data. In addition, to the best of our knowledge, the role of systemic chemotherapy in treating patients with adenocarcinoma of the appendix has not been assessed in any large national registry. Therefore, the purpose of the current study was to use the National Cancer Data Base (NCDB), which is a nationwide cancer database that captures approximately 70% of all newly diagnosed cancers in the United States, to: 1) assess the impact of histologic grade on overall survival (OS) for patients with mucinous and nonmucinous appendiceal neoplasms; and 2) to assess the impact of systemic chemotherapy on OS. MATERIALS AND METHODS Study Design We performed retrospective analyses of a cohort of patients diagnosed with appendiceal cancer from 1985 to The end date of follow-up was December Data Source and Study Population The source of data for this study was the NCDB. The NCDB is a nationwide cancer database sponsored by the Commission on Cancer of the American College of Surgeons and the American Cancer Society. Data capture from patients medical records is performed by trained cancer registrars. Only patients with topography code C18.1 of the third edition of the International Classification of Diseases for Oncology were eligible. The second and third edition histology codes selected were: mucinous (8470, 8480, and 8481), nonmucinous (8010, 8013, 8020, 8140, 8141, 8144, 8210, 8211, 8255, 8260, 8261, 8262, 8263, 8310, 8440, 8460, 8471, 8472, 8560, and 8574), and signet ring cell (8490). Excluded from further analysis were patients aged <18 years or > 90 years, those with unknown tumor stage, those with unknown treatment status, or those diagnosed at autopsy (Fig. 1). The variables of interest were age of the patient at the time of diagnosis, sex, grade (well-differentiated, moderately differentiated, poorly differentiated, undifferentiated/ Figure 1. Schematic representation of patient selection for final analysis. NCDB indicates National Cancer Data Base. anaplastic, and unknown), systemic chemotherapy status, type of surgical resection, stage of disease according to the seventh edition of the AJCC, and vital status. Stage was derived from the individual combinations of T, N, and M and only broad staging categories (stage I, II, III, and IV) could be derived because the seventh edition data components T4a, T4b, M1a, and M1b were not available to allow for stage subcategories. Details regarding the type of chemotherapy administered were not available. The types of surgical resection were: 1) local destruction or excision; 2) partial colectomy/segmental resection with or without resection of contiguous structures or organs; 3) subtotal colectomy with or without resection of contiguous structures or organs; 4) total colectomy/proctocolectomy with or without resection of contiguous structures or organs; 5) colectomy, not otherwise specified (NOS); and 6) surgery, NOS. No specific code for appendectomy exists in the NCDB but the partial colectomy/segmental resection code reflects and is defined as the performance of an appendetomy. 8 There are no specific codes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the NCDB. The different types of surgical resection were regrouped as follows for the cohort with stage I to III disease: 1) partial colectomy/segmental 214 Cancer January 15, 2016
3 Chemotherapy in Appendiceal Adenocarcinomas/Asare et al TABLE 1. Characteristics of Study Cohort by Histologic Type Characteristic Mucinous n55971 Nonmucinous n54805 Signet ring cell n51095 Age, y Mean Range Sex Female 3219 (53.9%) 2181 (45.4%) 696 (63.6%) Male 2752 (46.1%) 2624 (54.6%) 399 (36.4%) Grade Well differentiated 1919 (32.1%) 813 (16.9%) 16 (1.46%) Moderately differentiated 1414 (23.7%) 2316 (48.2%) 67 (6.1%) Poorly differentiated 658 (11.0%) 943 (19.6%) 527 (48.1%) Undifferentiated/anaplastic 44 (0.74%) 41 (0.85%) 42 (3.8%) Unknown 1936 (32.4%) 692 (14.4%) 443 (40.5%) AJCC stage I 526 (8.8%) 1031 (21.5%) 42 (3.8%) II 1811 (30.3%) 1671 (34.8%) 197 (18.0%) III 529 (8.9%) 846 (17.6%) 169 (15.4%) IV 3105 (52%) 1257 (26.2%) 687 (62.7%) Chemotherapy No chemotherapy 2881 (48.2%) 2894 (60.2%) 395 (36.1%) Received chemotherapy 3090 (51.8%) 1911 (39.8%) 700 (63.9%) Surgery No surgical resection a 757 (12.7%) 436 (9.1) 119 (10.9%) Any type of surgical resection 5213 (87.3%) 4368 (90.9) 974 (89.1%) Abbreviation: AJCC, American Joint Committee on Cancer. a Includes local tumor destruction and local tumor excision. Figure 2. Overall survival (OS) stratified by (A) histologic type (11,871 patients), (B) grade (11,871 patients), (C) American Joint Committee on Cancer stage for mucinous histology (5971 patients), and (D) American Joint Committee on Cancer stage for nonmucinous histology (4805 patients). Cancer January 15,
4 TABLE 2. Multivariable Cox Proportional Hazards Regression Model to Predict Death for Cohort With AJCC Stage I to Stage III Disease Mucinous Nonmucinous Variable HR (95% CI) P HR (95% CI) P AJCC stage I Referent Referent II 1.55 ( ) < ( ) <.0001 III 3.68 ( ) ( ) <.0001 Grade 1 Referent Referent ( ) < ( ) ( ) < ( ) < ( ) ( ).01 Unknown 1.15 ( ) ( ).004 Sex Female Referent Referent Male 1.16 ( ) ( ) <.0001 Chemotherapy No Referent Referent Yes 0.79 ( ) ( ).004 Surgery Appendectomy a Referent Referent Right hemicolectomy a 0.79 ( ) ( ) <.0001 Colectomy a 1.0 ( ) ( ).4 Surgery, NOS 1.16 ( ) ( ).06 Age 1.03 ( ) < ( ) <.0001 Abbreviations: 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; HR, hazard ratio; NOS, not otherwise specified. a Includes resection of contiguous structures/organs. Colectomy refers to the complete removal of the colon. resection with or without resection of contiguous structures (appendectomy); 2) subtotal colectomy with or without resection of contiguous structures or organs (right hemicolectomy); 3) total colectomy/proctocolectomy with or without resection of contiguous structures or organs; and 5) surgery, NOS. Patients with stage IV disease were classified according to whether they received any type of surgical resection. Statistical Analysis All statistical analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC) and statistical significance was assumed for P values <.05. Data for continuous variables were reported as the mean- 6 standard deviation. Discrete values were reported as the number with the corresponding percentage. Hazard ratios (HRs) were reported as point estimates with 95% confidence intervals (95% CIs). OS estimates were calculated using the Kaplan-Meier method from the date of diagnosis to the date of death. Patients who were alive at the time of last follow-up were censored. Separate multivariable Cox regression models to predict death for patients with stage I to stage III mucinous and nonmucinous disease were developed using the variables of grade, sex, chemotherapy status, and type of surgical resection. Similar Cox regression models to predict death were built for patients with stage IV mucinous and nonmucinous disease using the variables of grade, sex, chemotherapy status, and whether they underwent surgical resection. Variables included in the Cox model were determined a priori based on clinical validity and previous studies. 6,8-10 RESULTS Clinicopathologic Characteristics Of 25,992 patients with tumors of the appendix recorded in the NCDB from 1985 to 2006, a total of 11,871 met the inclusion criteria for final analysis (Fig. 1). The distribution by histologic type was 5971 patients with mucinous (50.3%), 4805 patients with nonmucinous (40.5%), and 1095 patients with signet ring cell (9.2%) type (Table 1). The mean age at diagnosis was higher for patients with nonmucinous tumors ( years) compared with those with mucinous ( years) and signet ring cell-type ( years) tumors. The histological differentiation of well was more common in mucinous tumors whereas moderate and poor differentiation were more common in nonmucinous tumors (Table 1). Patients with signet ring cell-type histology were more likely to have stage IV disease (62.7%) compared with patients with mucinous (52%) and nonmucinous (26.2%) histologic types (Table 1). 216 Cancer January 15, 2016
5 Chemotherapy in Appendiceal Adenocarcinomas/Asare et al Figure 3. Overall survival (OS) stratified by American Joint Committee on Cancer stage, histology, and administration of chemotherapy (chemo) among (A) patients with stage II to III mucinous histology (2345 patients), (B) patients with stage II to III nonmucinous histology (2520 patients), (C) patients with well-differentiated stage IV tumors (1149 patients), (D) patients with moderately differentiated stage IV tumors (974 patients), and (E) patients with poorly differentiated stage IV tumors (786 patients). 1 indicates chemotherapy received; -, no chemotherapy received. For those patients who received systemic chemotherapy, administration occurred within 90 days from the time of diagnosis in >98% of patients. Survival The 5-year OS rates for the cohort based on the histologic type of tumor were 53.6%, 46.2%, and 24.7%, respectively, for mucinous, nonmucinous, and signet ring cell-type (Fig. 2A). Due to the small percentage of tumors with signet ring cell histology (9%), further analyses were limited to tumors with mucinous and nonmucinous histologies. When stratified by grade, the 5-year OS rates were 63.9%, 50.1%, 25.2%, 20.5%, and 46.9%, respectively, for tumors with well, Cancer January 15,
6 TABLE 3. Multivariable Cox Proportional Hazards Regression Model to Predict Death for Cohort With AJCC Stage IV Disease Mucinous Nonmucinous Variable HR (95% CI) P HR (95% CI) P Grade 1 Referent Referent ( ) < ( ) < ( ) < ( ) < ( ) < ( ).003 Unknown 1.34 ( ) < ( ).03 Sex Female Referent Referent Male 1.23 ( ) < ( ).002 Chemotherapy No Referent Referent Yes 0.95 ( ) ( ) <.0001 Surgery No resection a Referent Referent Any type of surgical resection 0.78 ( ) < ( ).0005 Age 1.02 ( ) < ( ) <.0001 Abbreviations: 95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; HR, hazard ratio. a Includes local tumor destruction and local tumor excision. moderate, poor, undifferentiated, and unknown grades, respectively (Fig. 2B). OS rates stratified by stage of disease for mucinous and nonmucinous histologic types are shown by the Kaplan-Meier plots in Figures 2C and 2D, respectively. The 5-year OS rates for patients with mucinous stage I to III disease were 74.9%, 63.2%, and 51.1%, respectively, for well, moderate, and poor differentiation (Supporting Information Fig. 1A). Patients with stage I to III, nonmucinous disease had 5-year OS rates of 68.9%, 59.6%, and 39.8% for well, moderate, and poor differentiation (Supporting Information Fig. 1B). Among patients with stage IV disease, the 5-year OS rates were 56.7%, 31.5%, and 11.3% for patients with mucinous tumors with well, moderate, and poor differentiation, whereas the 5-year OS rates were 29.7%, 11.2%, and 6%, respectively, for patients with nonmucinous tumors with well, moderate, and poor differentiation (Supporting Information Figs. 1C and 1D). Multivariable Cox Regression Analysis for Stage I to III Disease On multivariable analysis of patients with stage I to III disease, higher AJCC stage was associated with an increased risk of death for both patients with mucinous and nonmucinous histologic types (Table 2). Stage was found to be the strongest predictor of death for both mucinous (stage III: HR, 3.68; 95% CI, [P 5 003]) and nonmucinous histologies (stage III: HR, 2.76; 95% CI, [P<.0001]) (Table 2). Higher tumor grade predicted an increased risk of death for both mucinous and nonmucinous histologic types. Male sex also was found to be associated with an increased risk of death, although the association was higher for the nonmucinous histologic type (HR, 1.29; 95% CI, [P<.0001]) compared with mucinous histologic type (HR, 1.16; 95% CI, [P 5.02]) (Table 2). Among patients with localized disease, those who underwent a right hemicolectomy had a decreased risk of death compared with those who underwent an appendectomy for both mucinous and nonmucinous histological types. Among both mucinous and nonmucinous histologic types, there was an associated protective effect for patients who received systemic chemotherapy compared with those who did not receive chemotherapy (HR, 0.79; 95% CI, [P ] for mucinous; and HR, 0.84; 95% CI, [P 5.004] for nonmucinous) (Table 2). Among patients with stage II to III mucinous and nonmucinous histology, improved OS was observed for patients who received systemic chemotherapy (Figs. 3A and 3B). Multivariable Cox Regression Analysis for Stage IV Disease On multivariable analysis of patients with stage IV disease, receipt of chemotherapy was not found to be associated with improved survival in the cohort with mucinous histology (HR, 0.95; 95% CI, [P 5.3]), whereas patients with nonmucinous histology had improved survival when chemotherapy was administered (HR, 0.73; 95% CI, [P<.0001]) (Table 3). Because no code for cytoreductive surgery existed in the 218 Cancer January 15, 2016
7 Chemotherapy in Appendiceal Adenocarcinomas/Asare et al NCDB, we compared patients who did and did not undergo a surgical resection. There was a decreased risk of death among those patients who underwent surgical resection for both histologic types (mucinous: HR, 0.78; 95% CI, [P<.0001]; and nonmucinous: HR, 0.76; 95% CI, [P ]) (Table 3). Due to the heterogeneity in OS rates among patients with stage IV disease, OS stratified by histologic type, grade, and chemotherapy was assessed. There was no statistically significant difference in the median OS for patients with well-differentiated mucinous histology who received chemotherapy compared with those who did not receive chemotherapy (6.4 vs 6.5 years [P not significant]) (Fig. 3C) (Supporting Information Table 1). There was an improvement in the median OS between patients with stage IV mucinous disease who received chemotherapy compared with those who did not among those with moderately differentiated tumors (2.99 vs 1.64 years [P ]) and poorly differentiated tumors (1.57 vs 1.02 years [P ]) (Figs. 3D and 3E) (Supporting Information Table 1). DISCUSSION To the best of our knowledge, the current analysis represents the largest cohort of patients with appendiceal adenocarcinoma reported to date, and demonstrates the important interplay between mucinous histology, grade, and stage. Although grade was found to have a robust impact on survival for patients with stage IV mucinous compared with nonmucinous appendiceal adenocarcinoma, this impact was not observed among patients with stage I to III disease. Because significantly different outcomes were noted for patients with moderately and poorly differentiated mucinous appendiceal adenocarcinomas, these data support the removal of the current (seventh edition) AJCC manual s mucinous high-grade category. It is important to note that the results of the current study demonstrate a benefit to adjuvant chemotherapy for patients with localized disease, and indicate that the benefit is similar between patients with both mucinous and nonmucinous histologies. In contrast, the benefit of systemic chemotherapy for patients with stage IV disease was dependent on both histological subtype and grade because patients with well-differentiated mucinous appendiceal adenocarcinomas demonstrated no benefit from systemic chemotherapy. Similar to a prior report using the SEER database, the prognostic impact of grade was found to be similar for localized mucinous and nonmucinous histologies, but was markedly differed for stage IV mucinous and nonmucinous histologies. 8 The 5-year OS rate for patients with well-differentiated and moderately differentiated, mucinous, stage IV disease was 56.7% and 31.5%, respectively, which is in contrast to the 5-year OS rate of 11.3% for patients with poorly differentiated, mucinous, stage IV tumors. These data do not support the current categorization of moderately and poorly differentiated mucinous histologies into a single mucinous high-grade category, because a statistically significant near-doubling in the HR was observed between these 2 grades (1.92 vs 3.71). In contrast, there was no statistically significant difference noted between moderate and poor histological grades for nonmucinous stage IV disease. A recent SEER analysis found similar findings for stage IV disease, with HRs for moderately differentiated and poorly differentiated mucinous histologies of 1.6 and 4.9, respectively. 8 Further support for a 3-tier system for metastatic mucinous appendiceal adenocarcinomas was provided by a recent retrospective study that evaluated several histopathological features and demonstrated significant stratification of OS across a 3-tiered grading system. 9 To the best of our knowledge, this is the first data set to evaluate the role of systemic chemotherapy for the adjuvant treatment of appendiceal adenocarcinoma. Currently, the use of adjuvant chemotherapy is extrapolated from its benefit for colorectal cancer. The validity of such an extrapolation is uncertain. Although limited data exist regarding the molecular alterations of appendiceal adenocarcinomas, preliminary studies have suggested lower rates of both microsatellite instability and adenomatous polyposis coli (APC) mutations, which represent the common early genomic events driving the development of colorectal cancer In the current study, we demonstrated a statistically significant benefit from adjuvant chemotherapy that is similar for both mucinous (HR, 0.79) and nonmucinous (HR, 0.84) histologies. It is interesting to note that a much smaller percentage of patients with mucinous histology presented with stage III disease compared with nonmucinous histology (8.9% vs 17.6%). This was particularly evident for well-differentiated mucinous histology, because 4.9% of patients presented with stage III disease whereas 42.5% presented with either stage I or II disease and 52.6% presented with stage IV disease. This stage distribution supports a preferential peritoneal manner of spread for mucinous appendiceal adenocarcinomas in contrast to lymphatic spread. For welldifferentiated, mucinous appendiceal adenocarcinomas, this finding correlates with the histological primary lesion termed a low-grade appendiceal mucinous neoplasm, which is characterized by a pushing invasion with Cancer January 15,
8 subsequent fibrosis and a thinning of the appendiceal wall rather than a direct invasion through the appendiceal wall layers. 14 A major finding from the current study is the lack of a benefit for systemic chemotherapy for patients with mucinous, well-differentiated, stage IV disease. This finding is in agreement with the current consensus treatment approach of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for this subset of cancers with intraperitoneal involvement. 15 Although cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are used for higher-grade appendiceal adenocarcinomas, to the best of our knowledge the benefit of such an approach is less certain. Because 41% of patients in the current study with stage IV, mucinous, well-differentiated appendiceal adenocarcinoma received systemic chemotherapy as their first treatment, these data strongly support a change in clinical practice. Although a limited number of retrospective studies have evaluated chemotherapy for metastatic mucinous appendiceal adenocarcinomas, the interpretation of these data is inherently challenging due to the heterogeneity of behavior across histological grades and the indolent biology and generally good overall outcome for patients with well-differentiated tumors In what to our knowledge are the 2 largest retrospective reports evaluating systemic chemotherapy for appendiceal cancers, efficacy endpoints for chemotherapy were not analyzed across histological grades, and thus the impact of systemic chemotherapy for well-differentiated as opposed to poorly differentiated tumor grades could not be determined. 17,18 One prospective phase 2 study has been conducted in patients with mucinous appendiceal adenocarcinoma. 19 In this study of 40 patients with unresectable pseudomyxoma peritonei of appendiceal origin, semiquantitative reductions in mucinous deposition were noted in 6 patients (15%). 19 The 1-year and 2-year OS rates were 84% and 61%, respectively. In contrast, a retrospective study evaluating poorly differentiated or signet ring cell appendiceal adenocarcinomas demonstrated a response rate of 44%, a median progression-free survival of 6.9 months, and a median OS of 1.7 years. 20 The differential benefit of chemotherapy across tumor grade and histological subtypes is a reflection of the inherent differences in the biology across these various subsets of appendiceal adenocarcinomas. Although CSS rates were not available in the NCDB, the pattern of OS observed in the current study cohort mirrors the trend reported for CSS in studies using SEER data. The 5-year OS rates for patients with mucinous (53.6%) and signet ring cell (24.7%) histology reported herein are comparable to studies using SEER data, in which the 5-year CSS rates were 56% for mucinous and 22% for signet ring cell histologic subtypes. 8,10 The SEER studies reported a 5-year CSS rate of 54% for patients with nonmucinous histology whereas the 5-year OS rate from the current NCDB study was 46%. Similar to previously published literature, stage IV disease, female sex, and welldifferentiated grade were more common among the cohort of patients with mucinous adenocarcinoma compared with those with nonmucinous adenocarcinoma. 8 The current study has some important limitations. First, we excluded patients with missing data from the final analysis, which could potentially introduce bias. Second, the NCDB does not collect data regarding the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, or the type and method of administration of chemotherapy. Because treatment for appendiceal cancer is based on that for colorectal cancer, the systemic chemotherapy used is reflective of a fluoropyrimidinebased chemotherapy. For the years 2003 through 2006, the NCDB recorded the elapsed time from diagnosis to chemotherapy administration and during this time frame, <3% of all patients with stage IV mucinous appendiceal adenocarcinomas received chemotherapy on the same day as a surgical procedure. This finding strongly supports that the recording of chemotherapy in the NCDB reflects the use of systemic chemotherapy. Third, the surgical coding for an appendectomy is imperfect because a partial colectomy/segmental resection code reflects an appendectomy or cecectomy procedure. Fourth, the NCDB does not allow for the determination of disease-specific mortality. This limitation prevents direct comparison of survival estimates with those in other studies in which only CSS mortality was reported. Fifth, the high rate of unknown tumor grade within mucinous histology reflects a further limitation of the current study. This finding likely reflects the presence of multiple classification systems for lowcellularity, mucinous appendiceal neoplasms, such as mucinous carcinoma peritonei of low grade or high grade by Bradley et al or peritoneal mucinous carcinomatosis or disseminated adenomucinosis by Ronnett et al. 21,22 Our missing grade rate of 32% for mucinous histology is similar to the rate noted using the SEER database, in which a rate of 35% was noted. 8 Despite these limitations, to our knowledge the current study is the largest cohort of patients with appendiceal adenocarcinoma published to date. The current large, retrospective cohort study affirms the importance of histologic grade in predicting survival outcomes for patients with appendiceal adenocarcinoma. The evidence from this study does not support the current 220 Cancer January 15, 2016
9 Chemotherapy in Appendiceal Adenocarcinomas/Asare et al AJCC staging system for appendiceal adenocarcinomas, in which mucinous moderately differentiated and poorly differentiated tumors are classified as high grade and thus consideration should be given to classifying mucinous appendiceal adenocarcinomas into 3-tiers: well, moderately, and poorly differentiated. Patients with appendiceal adenocarcinoma with stage IV, mucinous, welldifferentiated histology do not benefit from systemic chemotherapy and cytoreductive surgery should be considered as the frontline treatment among these individuals. FUNDING SUPPORT No specific funding was disclosed. CONFLICT OF INTEREST DISCLOSURES Elliot A. Asare is supported by the American College of Surgeons Clinical Scholars in Residence Program. REFERENCES 1. McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the Surveillance, Epidemiology and End Results program, Cancer. 2002;94: Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum. 1998;41: Benedix F, Reimer A, Gastinger I, Mroczkowski P, Lippert H, Kube R. Primary appendiceal carcinoma epidemiology, surgery and survival: results of a German multi-center study. Eur J Surg Oncol. 2010;36: Cortina R, McCormick J, Kolm P, Perry RR. Management and prognosis of adenocarcinoma of the appendix. Dis Colon Rectum. 1995;38: Ito H, Osteen RT, Bleday R, Zinner MJ, Ashley SW, Whang EE. Appendiceal adenocarcinoma: long-term outcomes after surgical therapy. Dis Colon Rectum. 2004;47: Overman MJ, Fournier K, Hu CY, et al. Improving the AJCC/ TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg. 2013;257: Davison JM, Choudry HA, Pingpank JF, et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol. 2014; 27: Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol. 2012;19: Liu X, Mody K, de Abreu FB, et al. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clin Chem. 2014;60: Alakus H, Babicky ML, Ghosh P, et al. Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med. 2014;6: Taggart MW, Galbincea J, Mansfield PF, et al. High-level microsatellite instability in appendiceal carcinomas. Am J Surg Pathol. 2013; 37: Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27: Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30: Pietrantonio F, Maggi C, Fanetti G, et al. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist. 2014;19: Tejani MA, Ter Veer A, Milne D, et al. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. J Natl Compr Canc Netw. 2014;12: Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010;116: Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer. 2008;99: Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012;23: Bradley RF, Stewart JH 4th, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30: Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to pseudomyxoma peritonei. Am J Surg Pathol. 1995;19: Cancer January 15,
Appendix adenocarcinomas are rare and heterogeneous
ORIGINAL CONTRIBUTION Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma Omer Aziz, Ph.D., F.R.C.S. 1,2 Ihab Jaradat, F.R.C.S. 1 Bipasha
More informationSurgical Oncology, Mercy Medical Center, Baltimore, MD
Ann Surg Oncol (2012) 19:110 114 DOI 10.1245/s10434-011-1840-y ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY The Role of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients
More informationJoseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital
Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital jmisdraji@partners.org Low-grade appendiceal mucinous neoplasm (LAMN) High-grade appendiceal mucinous neoplasm (HAMN) Adenocarcinoma
More informationChibueze Onyemkpa 1, Alan Davis 1, Michael McLeod 1, Tolutope Oyasiji 1,2. Original Article
Original Article Typical carcinoids, goblet cell carcinoids, mixed adenoneuroendocrine carcinomas, neuroendocrine carcinomas and adenocarcinomas of the appendix: a comparative analysis of survival profile
More informationSyllabus. Appendiceal GCC and LAMN Navigating the Alphabet Soup in the Appendix. Appendiceal tumors. Summary provided Complete presentation
2016 Current Issues in Surgical Pathology Appendiceal GCC and LAMN Navigating the Alphabet Soup in the Appendix Syllabus Summary provided Complete presentation sanjay.kakar@ucsf.edu Sanjay Kakar, MD University
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationSurgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
More informationProtocol for the Examination of Specimens From Patients With Carcinoma of the Appendix
Protocol for the Examination of Specimens From Patients With Carcinoma of the Appendix Version: Appendix 4.0.0.1 Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC
More informationProtocol for the Examination of Specimens From Patients With Carcinoma of the Appendix
Protocol for the Examination of Specimens From Patients With Carcinoma of the Appendix Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC Staging Manual For
More informationKathleen A. Cummins 1, Gregory B. Russell 2, Konstantinos I. Votanopoulos 1, Perry Shen 1, John H. Stewart 1, Edward A. Levine 1.
Original Article Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) Kathleen A. Cummins 1, Gregory
More informationAppendix cancer mimicking ovarian cancer
Int J Gynecol Cancer 2002, 12, 768 772 CORRESPONDENCE AND BRIEF REPORTS Appendix cancer mimicking ovarian cancer P. A. GEHRIG *, J. F. BOGGESS*, D. W. OLLILA, P. A. GROBEN & L. VAN LE* *Division of Gynecologic
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationCytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease Results of the French multicentric database Université Lyon 1 Centre Hospitalo-Universitaire Lyon-Sud EA
More informationNatural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry
2015;112:872 876 Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry PETER L. JERNIGAN, MD, KOFFI WIMA, MS, DENNIS J. HANSEMAN, PhD, RICHARD
More informationStaging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates
Staging Challenges in Lower GI Cancers Sanjay Kakar, MD University of California, San Francisco March 05, 2017 Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education
More informationEarly identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients: a new approach to surveillance for peritoneal metastasis
Foster et al. World Journal of Surgical Oncology (2016) 14:243 DOI 10.1186/s12957-016-0996-0 RESEARCH Open Access Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients:
More informationCOLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini
UNIVERSITY OF PERUGIA Department of General and Emergency Surgery Chief: Prof. Annibale Donini COLON CANCER PERITONEAL CARCINOMATOSIS TREATMENT Prof. Annibale Donini COLON CANCER IS A HIGHLY FREQUENT NEOPLASIA
More informationUpdate on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017
Update on staging colorectal carcinoma, the 8 th edition AJCC Dale C. Snover, MD November 3, 2017 General overview of staging Reason for uniform staging Requirements to use AJCC manual and/or CAP protocols
More informationChapter 6 Frozen Section Evaluation of the Appendix
Chapter 6 Frozen Section Evaluation of the Appendix Abstract Appendiceal tumors are rarely diagnosed preoperatively, and their classification is both challenging and controversial owing to their tendency
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationColon and Rectum: 2018 Solid Tumor Rules
2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING Colon and Rectum: 2018 Solid Tumor Rules 1 Colon and Rectum Solid Tumor Rules Separate sections for: Introduction Changes from 2007 MP/H rules Equivalent
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationTREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital Incidence, prevalence and risk factors for peritoneal
More informationProtocol for the Examination of Specimens From Patients With Carcinoma of the Appendix
Protocol for the Examination of Specimens From Patients With Carcinoma of the Appendix Protocol applies to all carcinomas arising in the vermiform appendix, including goblet cell carcinoid tumors. Other
More informationRamya Thota 1, Xiang Fang 2, Shanmuga Subbiah 3. Introduction
Original Article Clinicopathological features and survival outcomes of primary signet ring cell and mucinous adenocarcinoma of colon: retrospective analysis of VACCR database Ramya Thota 1, Xiang Fang
More informationDisseminated Peritoneal Adenomucinosis Associated with a Panperitonitis-Like Onset: Report of a Case
Surg Today (2001) 31:646 650 Disseminated Peritoneal Adenomucinosis Associated with a Panperitonitis-Like Onset: Report of a Case Yoshito Kuroki 1, Shunyou Otagiri 1, and Kazuhiro Tsukada 2 1 Department
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationProtocol for the Examination of Specimens from Patients with Carcinoma of the Appendix
Protocol for the Examination of Specimens from Patients with Carcinoma of the Appendix Protocol applies to all carcinomas arising in the vermiform appendix, including goblet cell carcinoid tumors. Other
More informationPATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY
PATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY Jeannelyn S. Estrella, MD Department of Pathology The UT MD Anderson Cancer
More informationShore Medical Center Site-Specific Study: Colorectal Cancer 2013
Shore Medical Center Site-Specific Study: Colorectal Cancer Shore Medical Center Site-Specific Study: Colorectal Cancer The following report is the result of a collaborative effort of four physician members
More informationA DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY. Helen Mari Parsons
A Culture of Quality? Lymph Node Evaluation for Colon Cancer Care A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY Helen Mari Parsons IN PARTIAL FULFILLMENT
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedures overview of complete cytoreduction Introduction (Sugarbaker technique) for pseudomyxoma peritonei
More informationManagement of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms
Management of an Appendiceal Mass - Approach to acute presentation of appendiceal neoplasms Dr. Claudia LY WONG, Department of Surgery, Kwong Wah Hospital Joint Hospital Surgical Grand Round Presentation,
More informationColorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY
Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details
More informationDrug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei
Ann Surg Oncol (2015) 22:S810 S816 DOI 10.1245/s10434-015-4675-0 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma
More informationColorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC
Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC 2 Epidemiology Colorectal Cancer is the 2 nd Leading Cause of Cancer-related
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationQué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites.
Qué operar y que no operar en carcinomatosis peritoneal. Indicaciones y límites. Dr. Pere Bretcha Boix Plataforma de Oncología Hospital quironsalud Torrevieja 1 20-year survival of 70% 2 Appendiceal Neoplasms
More informationINTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)
UnitedHealthcare Commercial Medical Policy INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: SUR052 Effective Date: January 1, 2019 Table of Contents Page INSTRUCTIONS FOR
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationGastrointestinal and Hernia Ward, Ningbo No.2 Hospital, Xibei Street 41, Ningbo, Zhejiang, China. * Equal contributors.
Int J Clin Exp Med 2017;10(5):8165-8173 www.ijcem.com /ISSN:1940-5901/IJCEM0045461 Original Article Impact of primary tumor location on the overall survival of patients with stage IV colorectal cancer:
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationCytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol
Ann Surg Oncol (2013) 20:4224 4230 DOI 10.1245/s10434-013-3145-9 ORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch
More informationAppendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome
Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome Walid Shaib, Emory University Kavya Krishna, Ohio State University
More informationCharacteristics, treatment patterns, and survival outcomes of primary GI melanoma cases compared to cutaneous melanoma, SEER:
Characteristics, treatment patterns, and survival outcomes of primary GI melanoma cases compared to cutaneous melanoma, SEER:1973-2015 Amanda Kahl, MPH Mary E. Charlton, PhD, Imran Hassan, MD, Paolo Goffredo,
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationGOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
More informationGOBLET CELL CARCINOID
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
More informationStage II III colon cancer: a comparison of survival calculators
Original Article Stage II III colon cancer: a comparison of survival calculators Riccardo Lemini 1, Kristopher Attwood 2, Stacey Pecenka 3, Juliet Grego 3, Aaron C. Spaulding 3, Steven Nurkin 4, Dorin
More informationReview Article Pulmonary Metastasis from Pseudomyxoma Peritonei
Gastroenterology Research and Practice Volume 2012, Article ID 690256, 6 pages doi:10.1155/2012/690256 Review Article Pulmonary Metastasis from Pseudomyxoma Peritonei Toshiyuki Kitai Department of Surgery,
More informationA Survay on Appendiceal Involvement in Ovarian Mucinous Tumors
http://www.ijwhr.net Open Access doi 10.15296/ijwhr.2018.33 Original Article International Journal of Women s Health and Reproduction Sciences Vol. 6, No. 2, April 2018, 199 203 ISSN 2330-4456 A Survay
More informationLower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance
Original Article Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance Dedrick Kok Hong Chan 1,2, Ker-Kan Tan 1,2 1 Division of Colorectal Surgery, University
More informationDoes the Retrieval of at Least 15 Lymph Nodes Confer an Improved Survival in Patients with Advanced Gastric Cancer?
J Gastric Cancer 2014;14(2):111-116 http://dx.doi.org/10.5230/jgc.2014.14.2.111 Original Article Does the Retrieval of at Least 15 Lymph Nodes Confer an Improved Survival in Patients with Advanced Gastric
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More informationTrends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma
Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytoreduction and Hyperthermic Page 1 of 10 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the
More informationBasic Data. Birthday: Gender:Female Admission date:
Basic Data Birthday:1951-07-02 Gender:Female Admission date:2004-06-28 Chief Complaint A protruding mass over RLQ abdomen for many years. Present Illness & Past History Pseudomyxoma peritonei s/p laparotomy
More informationRegional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies
Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies Byrne Lee, MD FACS Chief, Mixed Tumor Surgery Service City of Hope Division of Surgical Oncology September
More informationOverview. Collecting Cancer Data: Colon 11/5/2009. Collecting Cancer Data: NAACCR Webinar Series 1. Agenda NAACCR WEBINAR SERIES
Collecting Cancer Data: Colon 11/5/2009 Collecting Cancer Data: Colon/Rectum/Appendix NAACCR 2009 2010 WEBINAR SERIES Agenda Overview Treatment MP/H Rules CSv2 2 Overview Colon/Rectum/Appendix 2009 2010
More informationDifferential lymph node retrieval in rectal cancer: associated factors and effect on survival
Original Article Differential lymph node retrieval in rectal cancer: associated factors and effect on survival Cedrek McFadden 1, Brian McKinley 1, Brian Greenwell 2, Kaylee Knuckolls 1, Patrick Culumovic
More informationThe New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process
The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process Wednesday, April 29, 2009 at 11 AM Central M. Asa Carter, CTR Manager, Approvals and Standards
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationDespite advances in our understanding of appendiceal. An Update on the Diagnosis, Grading, and Staging of Appendiceal Mucinous Neoplasms
REVIEW ARTICLE An Update on the Diagnosis, Grading, and Staging of Appendiceal Mucinous Neoplasms Mark A. Valasek, MD, PhD* and Reetesh K. Pai, MD Abstract: Despite advances in our understanding of appendiceal
More informationManagement of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Surgical Oncology Department Management of Pseudomyxoma Peritonei (PMP) and Colon Cancer Carcinomatosis by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 21/04/2010 THERMOMETRY 1000-1500
More informationCorporate Medical Policy
Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2018 3/2019
More informationCOLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING
COLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING COLON AND RECTUM SOLID TUMOR RULES Separate sections for: Introduction Changes from 2007 MP/H rules Equivalent Terms Terms that are NOT Equivalent
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP278 Section: Medical Benefit Policy Subject: Hyperthermia in Cancer Therapy (e.g., HIPEC) I. Policy: Hyperthermia in Cancer Therapy (e.g., HIPEC) II. Purpose/Objective:
More informationReconsideration of the optimal minimum lymph node count for young colon cancer patients: a population-based study
Guan et al. BMC Cancer (2018) 18:623 https://doi.org/10.1186/s12885-018-4428-0 RESEARCH ARTICLE Reconsideration of the optimal minimum lymph node count for young colon cancer patients: a population-based
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationThe TNM classification is a worldwide benchmark for reporting the
1 COMMENTARY The Process for Continuous Improvement of the TNM Classification Mary K. Gospodarowicz, M.D. 1 Daniel Miller, M.D., M.P.H. 2 Patti A. Groome, M.Sc., Ph.D. 3 Frederick L. Greene, M.D. 4 Pamela
More informationThe projection of short- and long-term survival for. Conditional Survival Among Patients With Carcinoma of the Lung*
Conditional Survival Among Patients With Carcinoma of the Lung* Ray M. Merrill, PhD, MPH; Donald Earl Henson, MD; and Michael Barnes, PhD Objective: One- and 5-year probabilities of survival or death change
More informationComparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population
DOI 10.1007/s10147-015-0812-9 ORIGINAL ARTICLE Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population Yasunobu
More informationVariations in Metastasis Site by Primary Location in Colon Cancer
Variations in Metastasis Site by Primary Location in Colon Cancer The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published
More informationSurvival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer
Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer Jayashree Kalpathy-Cramer PhD 1, William Hersh, MD 1, Jong Song Kim, PhD
More informationCare, 4 University of North Dakota, 5 Christiana Care Health System, 6 UMass Memorial Medical Center,
The American Society of Peritoneal Surface Malignancies consensus on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States Esquivel
More informationPerigastric lymph node metastases in gastric cancer: comparison of different staging systems
Gastric Cancer (1999) 2: 201 205 Original article 1999 by International and Japanese Gastric Cancer Associations Perigastric lymph node metastases in gastric cancer: comparison of different staging systems
More informationJoseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital
Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital jmisdraji@partners.org Adenoma Low-grade appendiceal mucinous neoplasm High-grade appendiceal mucinous neoplasm Adenocarcinoma Serrated
More informationClinicopathological features and prognosis of pseudomyxoma peritonei
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 185-190, 2014 Clinicopathological features and prognosis of pseudomyxoma peritonei HUAN WANG 1*, XUEJUN WANG 2*, YANFANG JU 1, JINLIANG WANG 1, XIN ZHANG 1, YAO
More informationCancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS)
O COLON MEASURE SPECIFICATIONS Cancer Programs Practice Profile Reports (CP 3 R) Rapid Quality Reporting System (RQRS) Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff
More informationAJCC Cancer Staging 8 th Edition
AJCC Cancer Staging 8 th Edition Colon and Rectal Cancer Staging Update Webinar George J Chang, MD, MS Deputy Chair, Department of Surgical Oncology Chief, Colon and Rectal Surgery Professor of Surgical
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationGOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles hanlinwang@mednet.ucla.edu Goblet cell carcinoid (GCC) is a unique type of mixed endocrine-exocrine neoplasm, almost exclusively
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationMP Hyperthermic Intraperitoneal Chemotherapy for Select IntraAbdominal and Pelvic Malignancies. Related Policies None
Medical Policy MP 2.03.07 BCBSA Ref. Policy: 2.03.07 Last Review: 10/18/2018 Effective Date: 01/25/2019 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationOFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM
OFCCR CLINICAL DIAGNOSIS AND TREATMENT FORM Name: _, OFCCR # _ OCGN # _ OCR Group # _ HIN# Sex: MALE FEMALE UNKNOWN Date of Birth: DD MMM YYYY BASELINE DIAGNOSIS & TREATMENT 1. Place of Diagnosis: Name
More informationResults of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei
Results of CRS and HIPEC in Colorectal PSM and Pseudomyxoma Peritonei K. Van der Speeten 05/10/12 Introduction Results Morbidity & Mortality Adjuvant HIPEC Conclusions K. Van der Speeten Introduction PSM
More informationMP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Medical Policy MP 2.03.07 Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic BCBSA Ref. Policy: 2.03.07 Last Review: 07/25/2018 Effective Date: 07/25/2018
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More information